| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
T2 Biosystems, Inc. [ TTOO ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 04/12/2024 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 04/12/2024 | A | 682,036 | A | (1) | 682,036 | I | By CRG Partners III L.P.(2) | ||
| Common Stock | 04/12/2024 | A | 424,716 | A | (1) | 424,716 | I | By CRG Partners III - Parallel Fund (A) L.P.(2) | ||
| Common Stock | 04/12/2024 | A | 136,409 | A | (1) | 136,409 | I | By CRG Partners III (Cayman) Unlev AIV I L.P.(2) | ||
| Common Stock | 04/12/2024 | A | 1,647,315 | A | (1) | 1,983,262 | I | By CRG Partners III (Cayman) Lev AIV I L.P.(2) | ||
| Common Stock | 04/12/2024 | A | 390,142 | A | (1) | 878,415 | I | By CRG Partners III - Parallel Fund B (Cayman) L.P.(2) | ||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Series A Convertible Preferred Stock | (3) | 04/12/2024 | A | 17,160.48 | 04/12/2024 | (4) | Common Stock | 1,716,048 | $0 | 28,035.73 | I | By CRG Partners III - Parallel Fund B (Cayman) L.P.(2) | |||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
|
| Explanation of Responses: |
| 1. Pursuant to that certain Securities Purchase Agreement, dated February 15, 2024, by and among the Company, CRG Partners III L.P., CRG Partners III - Parallel Fund (A) L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III - Parallel Fund B (Cayman) L.P. (collectively, the "CRG Entities"), the CRG Entities received these shares of common stock in exchange for the CRG Entities surrendering for cancellation of certain outstanding debt. |
| 2. CR Group L.P. may be deemed to beneficially own these shares by virtue of its position as the investment manager for the CRG Entities. |
| 3. Each share of Series A Convertible Preferred Stock (the "Series A Preferred") converts into 100 shares of the Company's common stock at the holder's election, subject to beneficial ownership limitations, including that a holder of Series A Preferred is prohibited from converting such shares into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 49.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. As a result of the 49.99% beneficial ownership limitation, as of April 12, 2024, the Series A Preferred held by the reporting persons can be converted into a maximum of 1,173,600 shares of common stock in the aggregate. The shares of Series A Preferred have no expiration date. |
| 4. The preferred stock has no expiration date. |
| /s/ Nathan D. Hukill, authorized signatory for CR Group LP, CRG Partners III LP, CRG Partners III - Parallel Fund (A) LP, CRG Partners III (Cayman) Unlev AIV I LP, CRG Partners III (Cayman) Lev AIV I LP, and CRG Partners III - Parallel Fund B (Cayman) LP | 04/16/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||